Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This research is studying how a food product (resistant potato starch) which is a dietary supplement made from potato starch affects the gut bacteria of people with cirrhosis and hepatic encephalopathy.
The researchers in this study want to understand how potato starch works in the subject's body and how the body will react to it. Along with taking the study product participants health-related information and stool will be collected for this research study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Resistant potato starch | Experimental | This will be taken for four weeks by enrolled participants. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Resistant Potato Starch | Other | Participants will receive 4 weeks of resistant potato starch 20 grams (g) twice daily. Bob's Red Mill® potato starch will be used. Every patient will receive the same dose and there are no dose titrations. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in stool short-chain fatty acid (SCFA) levels from baseline to week 4 | The study team will compare the total concentrations of the 3 most abundant SCFAs in humans (acetate, propionate, and butyrate) at baseline and week 4. Stool will undergo SCFA quantification by the University of Michigan Metabolomics core. | Baseline, Week 4 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in animal naming test (ANT) from baseline to week 4 | In this test patients name as many animals as they can in 60 seconds. The ANT score is the number of unique animals named. | Baseline, Week 4 |
| Number and type of adverse events from baseline to week 8 |
Not provided
Inclusion Criteria:
Able to provide consent, with signed and dated informed consent form.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Diagnosis of cirrhosis based on liver biopsy, imaging, or evidence of clinical decompensation.
History of at least one episode of overt Hepatic Encephalopathy (HE) in the last year.
Sexually active women of childbearing potential enrolled in the study must agree to use a highly-effective method of contraception (defined in the protocol) for the duration of the study.
Exclusion Criteria:
Hospitalization in the last 4 weeks
Current refractory ascites (requiring large volume paracentesis to manage ascites)
Gut-absorbable or intravenous antibiotic therapy in the last 4 weeks (rifaximin is permitted)
Anticipated antibiotics in the coming 4 weeks
Use of lactulose in the last 4 weeks
Alcohol or illicit drug intake in the last 4 weeks
History of inflammatory bowel disease
History of primary sclerosing cholangitis
Total bilirubin in the last 3 months > 4 mg/dL
Prior diagnosis of dementia or other primary neurocognitive disorder
Pregnancy or breast feeding
Placement of a portosystemic shunt or transjugular intrahepatic portosystemic shunt in the last 3 months (permissible if placed >3 months before enrollment)
Allergy to resistant potato starch
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jenny Obst | Contact | 507-255-1337 | obst.jenny@mayo.edu |
| Name | Affiliation | Role |
|---|---|---|
| Patricia Bloom, MD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic | Recruiting | Rochester | Minnesota | 55902 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006501 | Hepatic Encephalopathy |
| D005355 | Fibrosis |
| ID | Term |
|---|---|
| D017093 | Liver Failure |
| D048550 | Hepatic Insufficiency |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The severity or grade of an adverse event may be measured using the following definitions: Mild: Noticeable to the subject, but does not interfere with subject's expected daily activities, usually does not require additional therapy or intervention, dose reduction, or discontinuation of the study. Moderate: Interferes with the subject's expected daily activities, may require some additional therapy or intervention but does not require discontinuation of the study. Severe: Extremely limits to the subject's daily activities and may require discontinuation of study therapy, and/or additional treatment or intervention to resolve and may be life-threatening or fatal. |
| baseline to week 8 |
| Change in T-score for the Patient Reported Outcomes Measurement Information System (PROMIS) gastrointestinal diarrhea 6a baseline to week 4 | Gastrointestinal questionnaire has six questions with a total score ranging from 1-30 with the lower score indicating a healthier status. | Baseline, Week 4 |
| Change in T-score for the PROMIS Gastrointestinal Gas and Bloating 13a scale baseline to week 4 | The Gas and Bloating scale has13 questions (scale 2-60; with higher scores corresponding to more severe gas/bloating). | Baseline, Week 4 |
| Number of patients enrolled in the study as a proportion of the number of patients contacted by the study team | start of screening, end of enrollment (approximately 20 months) |
| Feasibility of completing study activities | Proportion of study activities completed | baseline, week 8 |
| Feasibility based on the number of specimens collected | Proportion of study samples collected (number collected from all patients / number requested from patients). | baseline, week 4 |
| Retention to end of study | Proportion of drop outs | start of screening, end of enrollment (approximately 20 months) |
| Intervention adherence | Proportion of doses consumed | baseline, week 4 |
| Mayo Clinic | Recruiting | Rochester | Minnesota | 55905 | United States |
| D001928 |
| Brain Diseases, Metabolic |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |